This is a Hansoh news story, published by CNBC, that relates primarily to Merck news.
For more Hansoh news, you can click here:
more Hansoh newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from CNBC, you can click here:
more news from CNBCOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
booming obesity drug market. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest experimental weight loss pill news, Hansoh Pharma news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Chinese drugmaker Hansoh PharmaCNBC
•
85% Informative
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in milestone payments and royalties on sales.
The oral drug has not yet entered human trials, and Merck did not specify which diseases it plans to test the drug on first .
Several other drugmakers, including Pfizer and Roche , are racing to develop more convenient obesity pills.
VR Score
90
Informative language
93
Neutral language
65
Article tone
formal
Language
English
Language complexity
51
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
1
Source diversity
1
Affiliate links
no affiliate links